<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dendritic cell (DC)-specific intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-3-grabbing non-integrin (DC-SIGN) is a type II transmembrane C-type lectin expressed on DCs such as myeloid DCs and monocyte-derived DCs (MoDCs) </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we have reported that DC-SIGN interacts with carcinoembryonic antigen (CEA) expressed on colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells </plain></SENT>
<SENT sid="2" pm="."><plain>CEA is one of the most widely used <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers for <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e> such as <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, other groups have reported that the level of Mac-2-binding protein (Mac-2BP) increases in patients with pancreatic, breast, and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancers</z:e>, <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infections</z:e> such as human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C virus, and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we first identified Mac-2BP expressed on several colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines as a novel DC-SIGN ligand through affinity chromatography and mass spectrometry </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, we found that DC-SIGN selectively recognizes Mac-2BP derived from some colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> but not from the other ones </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, we found that the Î±1-3,4-<z:chebi fb="0" ids="33984">fucose</z:chebi> moieties of Le <z:chebi fb="0" ids="18154">glycans</z:chebi> expressed on DC-SIGN-binding Mac-2BP were important for recognition </plain></SENT>
<SENT sid="7" pm="."><plain>DC-SIGN-dependent cellular interactions between immature MoDCs and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells significantly inhibited MoDC functional maturation, suggesting that Mac-2BP may provide a tolerogenic microenvironment for colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cells through DC-SIGN-dependent recognition </plain></SENT>
<SENT sid="8" pm="."><plain>Importantly, Mac-2BP was detected as a predominant DC-SIGN ligand expressed on some primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues from certain parts of patients in comparison with CEA from other parts, suggesting that DC-SIGN-binding Mac-2BP bearing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated Le <z:chebi fb="0" ids="18154">glycans</z:chebi> may become a novel potential <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> biomarker for some patients instead of CEA </plain></SENT>
</text></document>